Health care stocks were falling premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.8% and the iShares Biotechnology ETF (IBB) 1.4% lower.

UniQure (QURE) shares were down more than 41% after the company said it has been notified by the US Food and Drug Administration that data from its phase I/II studies are not sufficient to provide the primary evidence of effectiveness needed to back a marketing application for AMT-130, an investigational gene therapy for Huntington's disease.

Zoetis (ZTS) said that it has agreed to acquire Neogen's (NEOG) animal genomics business for $160 million. Neogen shares were up more than 8% pre-bell.

Xeris Biopharma (XERS) stock was up more than 14% after the company reported that it swung to Q4 earnings as revenue increased during the period.